Cathy has covered prescription drug reimbursement issues for nearly 20 years, starting with the implementation of the Medicare Part D program. She has written extensively about developments in all the major US insurance sectors -- Medicare (Parts D and B), Medicaid and the employer-sponsored market. She has closely followed the increasing influence of pharmacy benefit managers and their use of formulary negotiations and rebates to control pricing. Cathy also has covered the implementation of frameworks for assessing drug value by medical professional organizations and the Institute for Clinical and Economic Review and is watching with interest as the government develops new policies aimed at lowering drug pricing.
For more than three decades, she has worked as a health care reporter and editor while raising three daughters. Cathy lives in Bethesda, MD with her husband Sean.
Latest From Cathy Kelly
But premiums in future years made need to keep pace with accelerating Medicare spending on Alzheimer’s drugs.
Eisai/Biogen’s promising Phase III data fueling the companies’ hopes that Medicare will relax coverage restrictions for their Alzheimer’s treatment candidate. If the sponsors fail to change the NCD, lecanemab will need to rely on a registry for reimbursement after full approval.
Centers for Medicare and Medicaid Services chief operating officer Jonathan Blum discusses implementation of an unprecedented new price setting program and how it might impact value-based pricing more broadly in a recent interview with Health Affairs.
A review of grants by the organization to a range of recipients engaged in work on lowering drug prices.
Study drills down into the lack of economic incentives for conducting confirmatory studies to inform policies that could remedy to the situation.
Fewer rebate penalties than lawmakers expected may be assessed in the coming year because of the current high rate of general inflation.